Please login to the form below

Not currently logged in
Email:
Password:

Merck Serono and Takeda reconsider matuzumab development

Merck Serono has announced it is considering whether to further develop its humanised monoclonal antibody drug matuzumab for metastatic colorectal cancer patients.

Merck Serono has announced it is considering whether to further develop its humanised monoclonal antibody drug matuzumab for metastatic colorectal cancer patients.

According to the company, a phase II trial investigating matuzumab in combination with irinotecan in patients with metastatic colorectal cancer (mCRC) who had already failed on multiple prior treatments, including irinotecan, has not met its predefined endpoint of activity.

Swtizerland-based Merck Serono is co-developing matuzumab with Japanese company Taked. According to a statement by Merck Serono, both companies share the view that the study results do not meet expectations.

The companies will continue to study the drug in other tumours including non-small cell lung cancer (NSCLC).

29th August 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Langland

Langland, a Publicis Health company, is the only health communications agency that thinks further across Clinical Trial Experience, Medical Strategy...

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...